Press Releases

Year

Jun 16, 2020

Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

FOSTER CITY, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today

Additional Formats

PDF Version

Jun 11, 2020

Vaxcyte Announces Pricing of Upsized Initial Public Offering

Foster City, CA, June 11, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the

Additional Formats

PDF Version

Jun 03, 2020

Vaxcyte Appoints Halley E. Gilbert to Board of Directors

Foster City, CA, June 3, 2020 – Vaxcyte, Inc ., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the

Additional Formats

PDF Version

May 21, 2020

SutroVax Announces Name Change to Vaxcyte

Foster City, CA, May 21, 2020 – SutroVax , Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately reflects the Company’s mission to improve global health by developing superior and novel vaccines designed to prevent or

Additional Formats

PDF Version

May 04, 2020

SutroVax Appoints Andrew Guggenhime as Chief Financial Officer and Chief Business Officer

Foster City, CA, May 4, 2020 – SutroVax , a biopharmaceutical company dedicated to the development of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the appointment of Andrew Guggenhime as Chief Financial

Additional Formats

PDF Version

Mar 26, 2020

SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

Foster City, CA, March 26, 2020 – SutroVax , a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of a $110 million Series D preferred stock

Additional Formats

PDF Version

Jan 30, 2020

SutroVax Announces Executive Appointment

Jim Wassil appointed Chief Operating Officer Foster City, CA, March 26, 2020 – SutroVax , a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing

Additional Formats

PDF Version